These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26764336)

  • 1. Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.
    Russo M; Naro A; Leo A; Sessa E; D'Aleo G; Bramanti P; Calabrò RS
    Pain Med; 2016 Jun; 17(6):1145-54. PubMed ID: 26764336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
    Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
    Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
    J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
    Giacoppo S; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
    Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
    Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
    Russo M; Calabrò RS; Naro A; Sessa E; Rifici C; D'Aleo G; Leo A; De Luca R; Quartarone A; Bramanti P
    Neural Plast; 2015; 2015():656582. PubMed ID: 25699191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
    Carotenuto A; Iodice R; Petracca M; Inglese M; Cerillo I; Cocozza S; Saiote C; Brunetti A; Tedeschi E; Manganelli F; Orefice G
    Acta Neurol Scand; 2017 Apr; 135(4):442-448. PubMed ID: 27500463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.
    Russo M; De Luca R; Torrisi M; Rifici C; Sessa E; Bramanti P; Naro A; Calabrò RS
    Eur Rev Med Pharmacol Sci; 2016 Jul; 20(14):3127-33. PubMed ID: 27460745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1219-28. PubMed ID: 23621668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of the effectiveness and safety of Sativex® in compassionate use].
    Cimas-Hernando I; Pato-Pato A; Lorenzo-González JR; Rodríguez-Constenla I
    Rev Neurol; 2015 Mar; 60(5):202-6. PubMed ID: 25710689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to pay for a treatment for pain in multiple sclerosis.
    Iskedjian M; Desjardins O; Piwko C; Bereza B; Jaszewski B; Einarson TR
    Pharmacoeconomics; 2009; 27(2):149-58. PubMed ID: 19254047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.